Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in High-Risk BCP-ALL (GRAALL-QUEST)
NCT03709719Phase 2Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2018
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Assistance publique - Hôpitaux de Paris. Started Oct 2018; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03709719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03709719.